FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2002406476> ?p ?o ?g. }

• W2002406476 endingPage "A134" @default.
• W2002406476 startingPage "A126" @default.
• W2002406476 abstract "Rotavirus is a leading cause of severe diarrhea in children under 5. In Argentina, the most affected regions are the Northeast and Northwest, where hospitalizations and deaths are more frequent. This study estimated the cost-effectiveness of adding either of the two licensed rotavirus vaccines to the routine immunization schedule.The integrated TRIVAC vaccine cost-effectiveness model from the Pan American Health Organization's ProVac Initiative (Version 2.0) was used to assess health benefits, costs savings, life-years gained (LYGs), DALYs averted, and cost/DALY averted of vaccinating 10 successive cohorts, from the health care system and societal perspectives. Two doses of monovalent (RV1) rotavirus vaccine and three doses of pentavalent (RV5) rotavirus vaccine were each compared to a scenario assuming no vaccination. The price/dose was US$ 7.50 and US$ 5.15 for RV1 and RV5, respectively. We ran both a national and sub-national analysis, discounting all costs and benefits 3% annually. Our base case results were compared to a range of alternative univariate and multivariate scenarios.The number of LYGs was 5962 and 6440 for RV1 and RV5, respectively. The cost/DALY averted when compared to no vaccination from the health care system and societal perspective was: US$ 3870 and US$ 1802 for RV1, and US$ 2414 and US$ 358 for RV5, respectively. Equivalent figures for the Northeast were US$ 1470 and US$ 636 for RV1, and US$ 913 and US$ 80 for RV5. Therefore, rotavirus vaccination was more cost-effective in the Northeast compared to the whole country; and, in the Northwest, health service's costs saved outweighed the cost of introducing the vaccine. Vaccination with either vaccine compared to no vaccination was highly cost-effective based on WHO guidelines and Argentina's 2011 per capita GDP of US$ 9090. Key variables influencing results were vaccine efficacy, annual loss of efficacy, relative coverage of deaths, vaccine price, and discount rate.Compared to no vaccination, routine vaccination against rotavirus in Argentina would be highly cost-effective with either vaccine. Health and economic benefits would be higher in the Northeast and Northwest regions, where the intervention would even be cost-saving." @default.
• W2002406476 created "2016-06-24" @default.
• W2002406476 creator A5011738603 @default.
• W2002406476 creator A5020490314 @default.
• W2002406476 creator A5035159936 @default.
• W2002406476 creator A5054329200 @default.
• W2002406476 creator A5070535394 @default.
• W2002406476 creator A5078271411 @default.
• W2002406476 creator A5078396987 @default.
• W2002406476 creator A5080737426 @default.
• W2002406476 creator A5084489575 @default.
• W2002406476 date "2015-05-01" @default.
• W2002406476 modified "2023-10-18" @default.
• W2002406476 title "Cost-effectiveness analysis of rotavirus vaccination in Argentina" @default.
• W2002406476 cites W1974762322 @default.
• W2002406476 cites W1979266518 @default.
• W2002406476 cites W2010973379 @default.
• W2002406476 cites W2017723456 @default.
• W2002406476 cites W2036408505 @default.
• W2002406476 cites W2040393189 @default.
• W2002406476 cites W2042889040 @default.
• W2002406476 cites W2055735989 @default.
• W2002406476 cites W2060271581 @default.
• W2002406476 cites W2071595116 @default.
• W2002406476 cites W2072301620 @default.
• W2002406476 cites W2076121434 @default.
• W2002406476 cites W2078790500 @default.
• W2002406476 cites W2085784554 @default.
• W2002406476 cites W2089710044 @default.
• W2002406476 cites W2095204653 @default.
• W2002406476 cites W2100178369 @default.
• W2002406476 cites W2101100687 @default.
• W2002406476 cites W2107362700 @default.
• W2002406476 cites W2118560211 @default.
• W2002406476 cites W2131154800 @default.
• W2002406476 cites W2143233237 @default.
• W2002406476 cites W2160702042 @default.
• W2002406476 cites W2170749337 @default.
• W2002406476 cites W70958447 @default.
• W2002406476 doi "https://doi.org/10.1016/j.vaccine.2014.12.074" @default.
• W2002406476 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25919152" @default.
• W2002406476 hasPublicationYear "2015" @default.
• W2002406476 type Work @default.
• W2002406476 sameAs 2002406476 @default.
• W2002406476 citedByCount "13" @default.
• W2002406476 countsByYear W20024064762015 @default.
• W2002406476 countsByYear W20024064762016 @default.
• W2002406476 countsByYear W20024064762017 @default.
• W2002406476 countsByYear W20024064762018 @default.
• W2002406476 countsByYear W20024064762020 @default.
• W2002406476 countsByYear W20024064762021 @default.
• W2002406476 countsByYear W20024064762023 @default.
• W2002406476 crossrefType "journal-article" @default.
• W2002406476 hasAuthorship W2002406476A5011738603 @default.
• W2002406476 hasAuthorship W2002406476A5020490314 @default.
• W2002406476 hasAuthorship W2002406476A5035159936 @default.
• W2002406476 hasAuthorship W2002406476A5054329200 @default.
• W2002406476 hasAuthorship W2002406476A5070535394 @default.
• W2002406476 hasAuthorship W2002406476A5078271411 @default.
• W2002406476 hasAuthorship W2002406476A5078396987 @default.
• W2002406476 hasAuthorship W2002406476A5080737426 @default.
• W2002406476 hasAuthorship W2002406476A5084489575 @default.
• W2002406476 hasConcept C112930515 @default.
• W2002406476 hasConcept C126322002 @default.
• W2002406476 hasConcept C144024400 @default.
• W2002406476 hasConcept C147483822 @default.
• W2002406476 hasConcept C149923435 @default.
• W2002406476 hasConcept C160735492 @default.
• W2002406476 hasConcept C162324750 @default.
• W2002406476 hasConcept C203014093 @default.
• W2002406476 hasConcept C22070199 @default.
• W2002406476 hasConcept C2777227250 @default.
• W2002406476 hasConcept C2779802037 @default.
• W2002406476 hasConcept C2780441014 @default.
• W2002406476 hasConcept C2780801004 @default.
• W2002406476 hasConcept C2781367151 @default.
• W2002406476 hasConcept C3019080777 @default.
• W2002406476 hasConcept C50522688 @default.
• W2002406476 hasConcept C515549039 @default.
• W2002406476 hasConcept C71924100 @default.
• W2002406476 hasConcept C99454951 @default.
• W2002406476 hasConceptScore W2002406476C112930515 @default.
• W2002406476 hasConceptScore W2002406476C126322002 @default.
• W2002406476 hasConceptScore W2002406476C144024400 @default.
• W2002406476 hasConceptScore W2002406476C147483822 @default.
• W2002406476 hasConceptScore W2002406476C149923435 @default.
• W2002406476 hasConceptScore W2002406476C160735492 @default.
• W2002406476 hasConceptScore W2002406476C162324750 @default.
• W2002406476 hasConceptScore W2002406476C203014093 @default.
• W2002406476 hasConceptScore W2002406476C22070199 @default.
• W2002406476 hasConceptScore W2002406476C2777227250 @default.
• W2002406476 hasConceptScore W2002406476C2779802037 @default.
• W2002406476 hasConceptScore W2002406476C2780441014 @default.
• W2002406476 hasConceptScore W2002406476C2780801004 @default.
• W2002406476 hasConceptScore W2002406476C2781367151 @default.
• W2002406476 hasConceptScore W2002406476C3019080777 @default.
• W2002406476 hasConceptScore W2002406476C50522688 @default.
• W2002406476 hasConceptScore W2002406476C515549039 @default.

• next